(Q34993934)

5 August 2017

1 reference

title

Experimental and clinical rationale for use of MMF in nontransplant progressive nephropathies (English)

1 reference

5 August 2017

Roberto Zatz

1

1 reference

5 August 2017

Irene Lourdes Noronha

series ordinal

2

1 reference

5 August 2017

Clarice Kazue Fujihara

series ordinal

3

1 reference

5 August 2017

publication date

1 December 2002

1 reference

American Journal of Physiology - Renal Physiology

5 August 2017

published in

1 reference

5 August 2017

volume

283

1 reference

5 August 2017

issue

6

1 reference

5 August 2017

page(s)

F1167-75

1 reference

Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00209.2002

Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00209.2002

Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00209.2002

Inhibition of endothelial receptor expression and of T-cell ligand activity by mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00209.2002

Nephron adaptation to renal injury or ablation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00209.2002

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00209.2002

Mycophenolate mofetil treatment for primary glomerular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00209.2002

Mycophenolic acid increases apoptosis, lysosomes and lipid droplets in human lymphoid and monocytic cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00209.2002

Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00209.2002

Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00209.2002

Lymphocyte-Selective Cytostatic and Immunosuppressive Effects of Mycophenolic Acid in Vitro: Role of Deoxyguanosine Nucleotide Depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00209.2002

Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00209.2002

Pathological expression of renin and angiotensin II in the renal tubule after subtotal nephrectomy. Implications for the pathogenesis of tubulointerstitial fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00209.2002

Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00209.2002

Mycophenolate mofetil aggravates postischemic acute renal failure in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00209.2002

Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00209.2002

The effect of mycophenolate mofetil and polyphenolic bioflavonoids on renal ischemia reperfusion injury and repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00209.2002

Inosine monophosphate dehydrogenase (IMPDH) inhibition in vitro suppresses lymphocyte proliferation and the production of immunoglobulins, autoantibodies and cytokines in splenocytes from MRLlpr/lpr mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00209.2002

Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00209.2002

Caught flat-footed: podocyte damage and the molecular bases of focal glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00209.2002

The safety and efficacy of MMF in lupus nephritis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00209.2002

Role of dietary protein and blood pressure in the progression of renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00209.2002

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00209.2002

Effect of mycophenolate mofetil on nitric oxide production and inducible nitric oxide synthase gene expression during renal ischaemia-reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00209.2002

Advanced glycosylation end products in patients with diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00209.2002

The use of mycophenolate mofetil in transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00209.2002

Use of mycophenolate mofetil in resistant membranous nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00209.2002

Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00209.2002

Mycophenolate mofetil prevents salt-sensitive hypertension resulting from nitric oxide synthesis inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00209.2002

In vitro effects of mycophenolic acid on the nucleotide pool and on the expression of adhesion molecules of human umbilical vein endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00209.2002

Mycophenolate mofetil (MMF, RS-61443) inhibits inflammation and smooth muscle cell proliferation in rat aortic allografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00209.2002

Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00209.2002

Mycophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00209.2002

Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00209.2002

Effect of mycophenolate mofetil on the progression of adriamycin nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00209.2002

Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the angiotensin type 2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00209.2002

Mycophenolate mofetil reduces renal cortical inducible nitric oxide synthase mRNA expression and diminishes glomerulosclerosis in MRL/lpr mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00209.2002

Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00209.2002

Mycophenolate mofetil impairs healing of left-sided colon anastomoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00209.2002

Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00209.2002

A BLINDED, RANDOMIZED CLINICAL TRIAL OF MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN CADAVERIC RENAL TRANSPLANTATION1

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00209.2002

10.1152/AJPRENAL.00209.2002

21 January 2018

Identifiers

DOI

0 references

1 reference